@gsk.com
We discover, develop and deliver medicines and vaccines to create value for patients and shareholders.
@gsk.comWhat if an infection was silently harming your body, but you had no idea it was there?
In this episode of GSK's Behind the Science podcast, Kat Arney, Joyeta Das, and Jessica Hicks explore the science and stigma of hepatitis B, an often-overlooked disease.
@gsk.comDementia is one of the greatest health challenges facing society today. We're proud to support The BARBARA Alliance in a major new partnership, announced today by UK Government, bringing together academia, charities and industry to help accelerate research.
Read more: gsk.to/4hELfAY
@gsk.com#News for #Investors and #Media: Today our specialist HIV company, ViiV Healthcare, announced phase III study results in #HIV evaluating a long-acting option versus daily oral therapy.
Our mission: to leave no person living with HIV behind.
👉 Find out more: gsk.to/1645
@gsk.com#News for #investors and #media: Today, we announced new positive data at #WCLC26 representing encouraging news for people living with ROS1-positive non-small cell lung cancer.
Learn more: gsk.to/4cJsjhu
@gsk.com#News for #investors and #media: Today, our licensor Hansoh Pharma presented positive data at #WCLC26 from a pivotal trial of an investigational antibody-drug conjugate in our pipeline.
Learn more: gsk.to/4xrKoZ1
@gsk.com#News for #Investors and #Media: Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a new prefilled syringe presentation of one of our vaccines.
Learn more: gsk.to/4xMvugV
@gsk.comThe data we’ve shared at #ERSCongress underscores how much more we can achieve for respiratory patients when science and partnership come together.
#ERSCongress
@gsk.comExcited to be there!
@gsk.comWe believe the future of respiratory care needs to be as diverse as the patients living with respiratory disease, supporting real-world use with longer-acting solutions that aim to offer greater choice and improve adherence.
@gsk.comWe'll see you there!
@gsk.comWe look forward to seeing you there!
@gsk.com#News for #Investors and #Media: Today we announced Phase II data for a seasonal flu vaccine candidate at #OPTIONSXIII.
Learn more: gsk.to/4iDDU5g
